These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 30032463

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients.
    Yoon JH, Kim JW, Jeon YW, Lee SE, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Lee JW, Min WS, Park CW, Cho SG.
    Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667
    [Abstract] [Full Text] [Related]

  • 23. Treatment of mantle cell lymphoma in older adults.
    Pease DF, Morrison VA.
    J Geriatr Oncol; 2018 Jul; 9(4):308-314. PubMed ID: 29325898
    [Abstract] [Full Text] [Related]

  • 24. 90Y-Ibritumomab Tiuxetan consolidation after autologous stem cell transplantation improves survival of patients with intermediate-/high-risk diffuse large B-cell lymphoma not responding adequately to first-line treatment.
    Mondello P, Pitini V, Arrigo C, Derenzini E, Mian M.
    Anticancer Res; 2014 Sep; 34(9):5121-5. PubMed ID: 25202102
    [Abstract] [Full Text] [Related]

  • 25. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C, Chen Z, Li Y.
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [Abstract] [Full Text] [Related]

  • 26. Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
    Witzig TE, Tobinai K, Rigacci L, Ikeda T, Vanazzi A, Hino M, Shi Y, Mayer J, Costa LJ, Bermudez Silva CD, Zhu J, Belada D, Bouabdallah K, Kattan JG, Kuruvilla J, Kim WS, Larouche JF, Ogura M, Ozcan M, Fayad L, Wu C, Fan J, Louveau AL, Voi M, Cavalli F.
    Ann Oncol; 2018 Mar 01; 29(3):707-714. PubMed ID: 29253068
    [Abstract] [Full Text] [Related]

  • 27. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.
    Semin Oncol; 2002 Feb 01; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [Abstract] [Full Text] [Related]

  • 28. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C, Kabadi SM, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z.
    Clin Ther; 2019 Nov 01; 41(11):2357-2379.e1. PubMed ID: 31699438
    [Abstract] [Full Text] [Related]

  • 29. Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospective study by the Finnish Lymphoma Group.
    Räty R, Honkanen T, Jantunen E, Jyrkkiö S, Karjalainen-Lindsberg ML, Kuittinen O, Lehto M, Mikkola M, Poikonen E, Rauhala A, Rimpiläinen J, Räsänen A, Siitonen S, Suominen M, Vapaatalo M, Elonen E.
    Leuk Lymphoma; 2012 Oct 01; 53(10):1920-8. PubMed ID: 22397313
    [Abstract] [Full Text] [Related]

  • 30. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
    Pejša V, Prka Ž, Lucijanić M, Mitrović Z, Piršić M, Jakšić O, Ajduković R, Kušec R.
    Croat Med J; 2017 Feb 28; 58(1):40-48. PubMed ID: 28252874
    [Abstract] [Full Text] [Related]

  • 31. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
    Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F, LYM-3002 investigators.
    Lancet Oncol; 2018 Nov 28; 19(11):1449-1458. PubMed ID: 30348538
    [Abstract] [Full Text] [Related]

  • 32. New developments in the management of diffuse large B-cell lymphoma.
    Habermann TM.
    Hematology; 2012 Apr 28; 17 Suppl 1():S93-7. PubMed ID: 22507791
    [Abstract] [Full Text] [Related]

  • 33. A treatment for activated B-cell-like DLBCL?
    Zinzani PL.
    Lancet Oncol; 2014 Aug 28; 15(9):916-7. PubMed ID: 25042201
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
    Hoster E, Delfau-Larue MH, Macintyre E, Jiang L, Stilgenbauer S, Vehling-Kaiser U, Salles G, Thieblemont C, Tilly H, Wirths S, Feugier P, Hübel K, Schmidt C, Ribrag V, Kluin-Nelemans JC, Dreyling M, Pott C, European MCL MRD Working Group and the European MCL Network.
    J Clin Oncol; 2024 Feb 10; 42(5):538-549. PubMed ID: 37992261
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prediction of Prognosis for Patients with Diffuse Large B-Cell Lymphoma Refractory to or in First Relapse After Initial R-CHOP Therapy: A Single-Institution Study.
    Yamamoto M, Watanabe K, Fukuda T, Miura O.
    Anticancer Res; 2017 May 10; 37(5):2655-2662. PubMed ID: 28476841
    [Abstract] [Full Text] [Related]

  • 38. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
    Fuji S, Kida S, Nakata K, Morishima T, Miyashiro I, Ishikawa J.
    Ann Hematol; 2021 Sep 10; 100(9):2253-2260. PubMed ID: 33169198
    [Abstract] [Full Text] [Related]

  • 39. Clinical Management Updates in Mantle Cell Lymphoma.
    Chen R, Sanchez J, Rosen ST.
    Oncology (Williston Park); 2016 Apr 10; 30(4):353-60. PubMed ID: 27083466
    [Abstract] [Full Text] [Related]

  • 40. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone.
    Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS.
    Leuk Lymphoma; 2010 May 10; 51(5):789-96. PubMed ID: 20367136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.